Associated Balance of Risk Score - Comprehensive Complication Index for the Prediction of Post-transplant Survival

Sponsor
European Hepatocellular Cancer Liver Transplant Group (Other)
Overall Status
Completed
CT.gov ID
NCT03723317
Collaborator
(none)
1,782
1
9
198.7

Study Details

Study Description

Brief Summary

In recent years, several scoring systems have been developed aimed at predicting early post-LT graft function. However, many of them showed poor efficacy when long-term survivals were tested. Moreover, the necessity to find an easy-to-use score represents another obstacle, with several scores composed by numerous, difficult to find, variables. Recently, the pre-LT Balance of Risk (BAR) and the post-LT Comprehensive Complication Index (CCI) have been created, but their external validation and integration in this setting is lacking.

This study aims at constructing an easy-to-use score system based on the combination of a small number of pre- and immediately post-liver transplant (LT) independent variables, in order to accurately predict long-term graft survival after LT.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Liver transplantation

Detailed Description

In the last years, several scoring systems have been developed with the intent to predict waiting-list mortality or early allograft dysfunction (EAD) after liver transplantation (LT). The Model for End-stage Liver Disease (MELD) is recognised as the most accurate liver allograft allocation model by prioritising patients according to the severity of their disease. However, several studies showed that MELD alone failed to predict early and late post-transplant clinical course. Consequently, other scoring systems based on pre-LT or post-LT variables have been developed, with the intent to identify high-risk cases for death, graft loss or re-transplantation (re-LT). Among them, two pre-LT scores, namely the D-MELD and Balance of Risk (BAR), showed to well predict early post-LT survival. Similarly, some post-LT scores were able to estimate EAD, and, thereby, to predict the probabilities of early re-LT and patient death. Interestingly, all of these scores, especially those based on pre-LT variables, resulted in a scarce prediction of long-term (five-year) survivals.

Recently, the Comprehensive Complication Index (CCI) has been developed in order to better capture complication rates after surgery. Some reports reported its excellent prognostic ability in different fields. However, up to now, no studies investigated the role of CCI concerning long-term prognostication of graft loss in LT.

This study aims at constructing an easy-to-use score system based on the combination of a small number of pre- and immediately post-LT independent variables, in order to accurately predict five-year post-LT graft survival. Both external and internal validations of the score were performed.

Study Design

Study Type:
Observational
Actual Enrollment :
1782 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Associated Balance of Risk Score - Comprehensive Complication Index for the Prediction of Long-term Survival After Liver Transplantation
Actual Study Start Date :
Jan 15, 2018
Actual Primary Completion Date :
Oct 15, 2018
Actual Study Completion Date :
Oct 15, 2018

Arms and Interventions

Arm Intervention/Treatment
Training liver transplantation

Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)

Procedure: Liver transplantation
First deceased-donor liver transplantation

Validation liver transplantation

Patients consecutively transplanted in the Karolinska Institute (N=520)

Procedure: Liver transplantation
First deceased-donor liver transplantation

Outcome Measures

Primary Outcome Measures

  1. Five-year post-transplant graft survival [5 years]

    Number of participants experiencing a graft loss for any reason

Secondary Outcome Measures

  1. Re-transplant rate [5 years]

    Number of participants experiencing a re-transplant for any reason

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • First transplant

  • adult (>18 years)

Exclusion Criteria:
  • living donation

  • re-transplant

  • combined transplant

  • domino transplant

  • paediatric transplant

Contacts and Locations

Locations

Site City State Country Postal Code
1 UCL Brussels Belgium

Sponsors and Collaborators

  • European Hepatocellular Cancer Liver Transplant Group

Investigators

  • Principal Investigator: Quirino Lai, MD PhD, UCL Brussels

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
European Hepatocellular Cancer Liver Transplant Group
ClinicalTrials.gov Identifier:
NCT03723317
Other Study ID Numbers:
  • #0003
First Posted:
Oct 29, 2018
Last Update Posted:
Oct 29, 2018
Last Verified:
Oct 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 29, 2018